Clopidogrel, given in combination with aspirin, may soon be the standard of care for both short- and long-term prevention of major cardiovascular events in patients with acute coronary syndromes (ACS). Data from the landmark CURE*trial demonstrating the value of this approach were presented at the 50th Scientific Session of the American College of Cardiology [Orlando, US; March 2001].